Trial Profile
A Randomized, Subject- and Investigator-blinded, Placebo Controlled Study to Assess the Safety, Pharmacokinetics and Efficacy of Intravenous Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Bimagrumab (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Novartis; Novartis Pharmaceuticals
- 06 Oct 2023 Results presented at the 59th Annual Meeting of the European Association for the Study of Diabetes
- 26 Jun 2023 Results (n=75), presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
- 30 Oct 2019 According to a Rhythm Pharmaceuticals media release, data from this trial will be presented during a late-breaking research forum titled "Emerging Pharmacological Anti-obesity Therapies." The research forum is part of the 37th Annual Meeting of The Obesity Society at ObesityWeek, taking place from Nov. 3-7, 2019, at Mandalay Bay South Convention Center, Las Vegas, Nev.